|1.||McEwan, Alexander J B: 3 articles (08/2015 - 12/2004)|
|2.||Stokkel, Marcel P M: 3 articles (07/2004 - 05/2003)|
|3.||Makis, William: 2 articles (08/2015 - 04/2015)|
|4.||McCann, Karey: 2 articles (08/2015 - 04/2015)|
|5.||Kundra, Vikas: 2 articles (10/2013 - 03/2002)|
|6.||Ahlman, Håkan: 2 articles (05/2013 - 07/2002)|
|7.||Nilsson, Ola: 2 articles (05/2013 - 07/2002)|
|8.||Wängberg, B: 2 articles (05/2012 - 02/2001)|
|9.||Forssell-Aronsson, E: 2 articles (05/2012 - 02/2001)|
|10.||Nilsson, O: 2 articles (05/2012 - 02/2001)|
10/01/2013 - "Biodistribution demonstrated significantly greater 111In-octreotide uptake in tumors from mice injected with CMV-TUSC2-IRES-SSTR2 or CMV-SSTR2 than the control plasmid, CMV-TUSC2 (p < .05). "
01/01/2005 - "(177)Lu-DOTATATE therapy can be effective in patients with progressive DTC who have no therapeutic options and sufficient uptake of (111)In-octreotide in tumor lesions as shown on (111)In-octreotide scintigraphy. "
09/01/2015 - "Three cases have been selected and presented from a series of patients that illustrate the utility of SPECT-CT studies with (111)In-octreotide in the diagnosis and monitoring of this type of tumor. "
05/01/2013 - "This study aimed to test the role of combined imaging with 18F-FDG-PET/CT and 111In-octreotide SPECT in characterizing thymic epithelial tumors (TETs). "
03/01/2002 - "Mice bearing tumors produced by transfected cells were injected with (111)In-octreotide for biodistribution and imaging studies. "
|2.||Neuroendocrine Tumors (Neuroendocrine Tumor)
09/01/2009 - "Hence for radionuclide therapy of neuroendocrine tumors, patients can be selected for therapy on the basis of gamma-emitting indium-111-octreotide imaging and treated with beta-emitting yttrium-90-octreotate. "
02/01/1996 - "In this study we have prospectively examined the ability of 111In-octreotide scintigraphy, magnetic resonance imaging (MRI), and computed tomography (CT) to localize tumor lesions in 24 patients with a biochemical or histologic diagnosis of neuroendocrine tumor. "
06/01/1995 - "Neuroendocrine tumors with somatostatin receptor expression may be localized by 111In-octreotide scintigraphy. "
10/01/2011 - "Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response."
10/01/2011 - "The aim of this study was to examine the efficacy of intra-arterial (90)Yttrium treatment in the management of unresectable hepatic neuroendocrine tumors (NET) metastases unresponsive to treatment and the role of (111)In-octreotide scintigraphy in the evaluation of treatment response. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/2010 - "Sensitivity and specificity for detection of hepatic metastases were 77% and 100% for CT, 82% and 100% for MR, 63% and 100% for (123)I-meta-iodobenzylguanadine scintigraphy, and 63% and 100% for (111)In-octreotide. "
07/01/2004 - "We conclude that (111)In-octreotide scintigraphy is a valuable clinical tool for the detection of non-functioning DTC metastases. "
12/01/2003 - "During follow-up multiple metastases were seen upon bone scintigraphy for which treatment with high doses Indium-111-octreotide was initiated. "
05/01/2003 - "In nine out of ten patients with a negative I-131 WBS, Indium-111-Octreotide demonstrated multiple metastases. "
03/01/1997 - "111In-octreotide scan also showed tracer uptake in five of the six patients with histologically proven axillary metastases, while four of these six patients showed 201Tl uptake. "
08/01/2008 - "111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas."
09/01/2015 - "(111)In-octreotide SPECT-CT in head and neck paragangliomas."
05/01/2012 - "Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy."
05/01/2012 - "A patient with metastatic paraganglioma (liver and bone metastases) underwent surgical removal of the primary after injection of 131I-meta-iodobenzylguanidine and 111In-octreotide. "
06/01/1993 - "In this study, we report the results of 111In-octreotide scintigraphy in 34 patients referred because of known paragangliomas or in whom a paraganglioma was suspected and compared the results of octreotide scintigraphy with the outcomes of other imaging techniques used in the diagnosis or follow-up of these patients. "
08/01/2009 - "All orbital meningiomas, including 14 ONSMs and 12 spheno-orbital meningiomas, showed high median (111)In-octreotide uptake ratios of 7.2 (range, 4.6-15.4) and 16.3 (range, 4.6-15.4), respectively. "
04/01/1996 - "Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results."
01/01/1996 - "We have studied prospectively 47 patients with CNS tumours including 16 meningiomas and 33 other tumours using combined 111In-octreotide and 99mTc-DTPA brain scintigraphy. "
11/01/1998 - "Before and 2-3 mo after surgery, 27 patients with meningioma received MRI as well as SRS after intravenous injection of 200 MBq 111In-octreotide. "
03/01/1995 - "111In-octreotide scintigraphy was shown to be very helpful in the in vivo differential diagnosis: all four meningiomas showed intense tracer uptake, while all 15 neurinomas were negative (P < 0.001 by Fisher's exact test). "
|5.||Somatostatin Receptors (Somatostatin Receptor)
|6.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|10.||Technetium Tc 99m Dimercaptosuccinic Acid